Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jaguar Health, Inc.JAGX · Entity 8387 | Director | May 18, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jaguar Health, Inc.
Report date May 18, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,133 |
Reported balance
After 2022-05-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-18 · Exercise / conversion · Acquired 12,133 · Balance 12,133 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-18 · Exercise / conversion · Disposed 12,133 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3: The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
F3: The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVADEL PHARMACEUTICALS PLC
Report date February 12, 2026 · Filed February 12, 2026
Section 16 reporting ended · disclosed 2026-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Disposition to issuer · Disposed 211,105 · Balance 0 F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-02-12 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F4: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2026-12-14 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-12 · Disposition to issuer · Disposed 150,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.95 · Expires 2027-12-12 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-12 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.06 · Expires 2028-03-22 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2029-03-07 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-12 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2029-05-30 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Disposition to issuer · Disposed 400,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Disposition to issuer · Disposed 500,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2031-12-07 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Disposition to issuer · Disposed 310,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.69 · Expires 2032-08-04 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-12 · Disposition to issuer · Disposed 350,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.57 · Expires 2034-02-20 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-12 · Disposition to issuer · Disposed 600,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.87 · Expires 2030-03-06 | Direct | 0 |
Reported balance
After 2026-02-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-12 · Disposition to issuer · Disposed 310,000 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.
F2: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR").
F3: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1.
F4: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary.
F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 310,000 | Not disclosed Strike: $7.87 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 12 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 310,000 shares Expires 2030-03-06 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 600,000 | Not disclosed Strike: $13.57 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 11 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 600,000 shares Expires 2034-02-20 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 350,000 | Not disclosed Strike: $4.69 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 10 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 350,000 shares Expires 2032-08-04 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 310,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 9 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 310,000 shares Expires 2031-12-07 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $6.79 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 8 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 500,000 shares Expires 2030-12-08 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $1.71 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 7 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 400,000 shares Expires 2029-05-30 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 6 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 100,000 shares Expires 2029-03-07 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $7.06 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 5 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2028-03-22 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $8.95 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 4 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 100,000 shares Expires 2027-12-12 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $10.40 | Not disclosed |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · derivative · entry 3 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 150,000 shares Expires 2026-12-14 F5 · kind: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · price: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Cash Consideration over the applicable exercise price per Ordinary Share under such Option and (ii) one CVR for each Ordinary Share subject to such Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerOrdinary Shares | 10,000 | $21.00 | $210,000.00 |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · nonDerivative · entry 2 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · kind: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F1 · price: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · price: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F4 · ownership.nature: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 17:32 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | Disposition to issuerOrdinary Shares | 211,105 | $21.00 | $4,433,205.00 |
DisclosureSEC source: 0001104659-26-014441 · tm266121-2_4seq1.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · kind: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). F3 · shares: Includes Ordinary Shares previously subject to vesting restrictions or forfeiture back to the Issuer (each, a "Restricted Stock Award"). Pursuant to the Transaction Agreement, at the Effective Time, each Restricted Stock Award that was outstanding immediately prior to the Effective Time vested in full and was treated in the manner described in footnote 1. F1 · price: Reflects the disposition of ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · price: Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $21.00 in cash (the "Cash Consideration") and a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share, contingent upon achievement of certain milestones (each a "CVR"). Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:06 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $7.87 | $0.00 |
DisclosureSEC source: 0001104659-25-021732 · tm258534-1_4seq1.xml · derivative · entry 3 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,000 Underlying: Ordinary Shares · 310,000 shares Expires 2030-03-06 F3 · derivative.exercise_date: The options shall vest, if at all, in four equal increments if the volume-weighted average price of the Issuer's Ordinary Shares during any 30 calendar day period exceeds $11, $14, $17 and $19.09, respectively. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:06 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantOrdinary Shares | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021732 · tm258534-1_4seq1.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,100 F1 · shares: Consists of a restricted share award. The restricted share award shall vest in equal annual installments on each of the first four anniversaries following the 3/5/2025 grant date. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 18:14 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseOrdinary Shares | 402 | $9.82 | $3,947.64 |
DisclosureSEC source: 0001104659-24-127300 · tm2430692-1_4seq1.xml · nonDerivative · entry 2 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 10,000 F2 · ownership.nature: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 18:14 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseOrdinary Shares | 9,598 | $9.98 | $95,759.25 |
DisclosureSEC source: 0001104659-24-127300 · tm2430692-1_4seq1.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 9,598 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.925 to $10.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary. Read SEC document |
| February 20, 2024 Filed Mar 4, 2024 06:24 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $13.57 | $0.00 |
DisclosureSEC source: 0001104659-24-030219 · tm247077-5_4seq1.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: ADSs · 600,000 shares Expires 2034-02-20 F1 · derivative.exercise_date: Options become exercisable as to 150,000 ADSs on each of the first four anniversaries after the 2/20/2024 grant date. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 10, 2023 Filed Aug 10, 2023 18:45 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 10,000 | $13.20 | $131,997.00 |
DisclosureSEC source: 0001104659-23-089935 · tm2323474-1_4seq1.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,100 F1 · security: The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.86 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 05, 2023 Filed Jun 5, 2023 21:29 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001104659-23-068234 · tm2317881-1_4seq1.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: ADSs · 350,000 shares Expires 2032-08-04 F1 · kind: On August 4, 2022, the Reporting Person was granted an option to purchase 350,000 ADSs, for which vesting was subject to the satisfaction of certain performance criteria. The performance criteria were met on June 5, 2023 (the "First Vesting Date"), resulting in the vesting of 50% of the ADSs underlying such option. The remaining ADSs will vest on the one year anniversary of the First Vesting Date, subject to the Reporting Person's continued service at such time. F1 · derivative.exercise_date: On August 4, 2022, the Reporting Person was granted an option to purchase 350,000 ADSs, for which vesting was subject to the satisfaction of certain performance criteria. The performance criteria were met on June 5, 2023 (the "First Vesting Date"), resulting in the vesting of 50% of the ADSs underlying such option. The remaining ADSs will vest on the one year anniversary of the First Vesting Date, subject to the Reporting Person's continued service at such time. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| May 27, 2022 Filed May 31, 2022 07:13 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 50,000 | $2.05 | $102,500.00 |
DisclosureSEC source: 0001104659-22-066221 · tm2217241-1_4seq1.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,100 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| May 18, 2022 Filed May 18, 2022 16:33 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionRestricted stock units · Derivative | 12,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-062476 · tm2215330-1_4seq1.xml · derivative · entry 2 Divis Gregory J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_price: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. F3 · derivative.exercise_date: The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units were previously reported as covering 36,400 shares, but were adjusted to reflect the Reverse Stock Split. Such restricted stock units were granted on May 18, 2021 and vested in full on May 18, 2022, the first anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 18, 2022 16:33 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | Exercise / conversionCommon Stock | 12,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-062476 · tm2215330-1_4seq1.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 21:43 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 85,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-040408 · tm2210715-2_4seq1.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,900 Underlying: Common Stock · 85,900 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · date: The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022. F4 · derivative.exercise_date: The restricted stock units vest in full on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F4 · derivative.expiration_date: The restricted stock units vest in full on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 18:45 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001179110-21-010795 · edgar.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: ADSs · 310,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: Options become exercisable as to 77,500 ADSs on each of the first four anniversaries after the 12/07/2021 grant date. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:02 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantRestricted stock units · Derivative | 36,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-069972 · a4.xml · derivative · entry 2 Divis Gregory J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,400 Underlying: Common Stock · 36,400 shares Expires not disclosed F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on May 18, 2021. F5 · derivative.exercise_date: The restricted stock units vest in full on May 18, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. F5 · derivative.expiration_date: The restricted stock units vest in full on May 18, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. Read SEC document |
| May 18, 2021 Filed May 20, 2021 17:02 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 72,750 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001104659-21-069972 · a4.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,750 Underlying: Common Stock · 72,750 shares Expires 2031-05-18 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option and restricted stock unit grants were approved by the issuer's board of directors on May 18, 2021. F3 · derivative.exercise_date: The options will vest in full on May 18, 2022, the first anniversary of the grant date, so long as the director continues to serve on the board of directors of the issuer. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 16:08 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0001179110-20-011791 · edgar.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: ADSs · 500,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: Options become exercisable as to 125,000 ADSs on each of the first four anniversaries after the 12/08/2020 grant date. F2 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 19:39 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 13,000 | $7.78 | $101,155.60 |
DisclosureSEC source: 0001179110-20-009023 · edgar.xml · nonDerivative · entry 1 Divis Gregory J · CIK 0001410677 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,100 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.69 to $7.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · balance_after: Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary). Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 21:30 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock option (right to buy) · Derivative | 26,533 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001104659-20-037929 · a4.xml · derivative · entry 1 Divis Gregory J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,533 Underlying: Common Stock · 26,533 shares Expires 2030-03-20 F1 · security: Granted pursuant to the issuer's 2014 Stock Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on March 20, 2020. F3 · derivative.exercise_date: The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the director remains employed by the issuer. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 17:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 19,000 | $5.13 | $97,470.00 |
DisclosureSEC source: 0001567619-19-021885 · doc1.xml · nonDerivative · entry 1 DIVIS GREG J · CIK 0001410677 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,100 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · balance_after: Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, of which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary). Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 16:52 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 121,573 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001104659-19-042088 · a4.xml · derivative · entry 1 DIVIS GREG J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,573 Underlying: Common Stock · 121,573 shares Expires 2022-07-24 F1 · security: Granted pursuant to the issuer's 2014 Equity Incentive Plan. F2 · date: The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding following the issuer's underwritten public offering that closed on July 23, 2019. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on July 24, 2019, such that the effective date of the option grant was July 24, 2019. F3 · derivative.exercise_date: Vests in equal monthly installments beginning on July 24, 2019, with one month of options, or 3,377 options, vested as of the grant date based on the reporting person's number of years of service on the issuer's board of directors, such that the grant is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 17:39 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001567619-19-012607 · doc1.xml · derivative · entry 6 DIVIS GREG J · CIK 0001410677 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: ADSs · 400,000 shares Expires 2029-05-30 F7 · derivative.exercise_date: Options become exercisable as to 100,000 ADSs on each of the first four anniversaries after the 5/30/2019 grant date. F1 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 19:04 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 100,000 | $1.85 Strike: $1.85 | $185,000.00 |
DisclosureSEC source: 0001567619-19-006609 · doc1.xml · derivative · entry 5 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: ADSs · 100,000 shares Expires 2029-03-07 F6 · derivative.exercise_date: Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 19:04 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantADSs | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-006609 · doc1.xml · nonDerivative · entry 1 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,100 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · balance_after: Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary). Read SEC document |
| July 11, 2018 Filed Jul 13, 2018 17:34 UTC | Jaguar Health, Inc. JAGX · Entity 8387 | GrantStock Option (right to buy) · Derivative | 104,860 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001104659-18-045068 · a4.xml · derivative · entry 1 DIVIS GREG J · CIK 0001410677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,860 Underlying: Common Stock · 104,860 shares Expires 2028-07-11 F1 · security: Granted pursuant to the Issuer's 2014 Equity Incentive Plan. F2 · date: The option grant was approved by the Issuer's board of directors on July 11, 2018. F3 · derivative.exercise_date: Vests in equal monthly installments, beginning on July 11, 2018, such that it is vested in full on the 3-year anniversary of the grant date. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 19:00 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 16,000 | $6.00 | $96,000.00 |
DisclosureSEC source: 0001140361-18-030198 · doc1.xml · nonDerivative · entry 1 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,100 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · balance_after: Includes 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant). Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 16:56 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 50,000 | $7.06 Strike: $7.06 | $353,000.00 |
DisclosureSEC source: 0001140361-18-014819 · doc1.xml · derivative · entry 4 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: ADSs · 50,000 shares Expires 2028-03-22 F5 · derivative.exercise_date: Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 3/22/2018 grant date. F1 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:15 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantStock Option (right to buy) · Derivative | 100,000 | $8.95 Strike: $8.95 | $895,000.00 |
DisclosureSEC source: 0001140361-17-046232 · doc1.xml · derivative · entry 3 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: ADSs · 100,000 shares Expires 2027-12-12 F4 · derivative.exercise_date: Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date. F1 · derivative.underlying: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:15 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | GrantADSs | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-046232 · doc1.xml · nonDerivative · entry 1 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · balance_after: Represents 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant). Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 17:03 UTC | AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991 | PurchaseADSs | 10,600 | $9.32 | $98,760.20 |
DisclosureSEC source: 0001140361-17-035544 · doc1.xml · nonDerivative · entry 1 DIVIS GREG J · CIK 0001410677 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 F1 · security: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.14 to $9.85, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.